Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07131813RecruitingPhase 4
Tofacitinib for oral lichen planus
This trial tests whether adding the drug tofacitinib to standard treatment helps reduce symptoms of oral lichen planus, a chronic inflammatory mouth condition. It is for people with moderate to severe disease who have not taken certain immune-suppressing medicines recently.
Bhubaneswar, OdishaAges 18 years+ - NCT07132775Recruiting
Full-body electrical stimulation suit for spasticity and pain
This study tests a full-body suit that delivers gentle electrical pulses to help reduce muscle stiffness, spasms, and pain in people with conditions like multiple sclerosis, fibromyalgia, or other neurological problems. It may help with movement and comfort.
Chicago, IllinoisAges 18–75 - NCT06932744RecruitingPhase 3
Testing a new PNH pill for people who haven't had complement therapy
This study tests a new oral medication called MY008211A for people with PNH who have not yet tried complement inhibitors. It aims to improve anemia and reduce the need for blood transfusions by targeting the part of the immune system that destroys red blood cells.
Beijing, Beijing MunicipalityAges 18–75 - NCT06932471RecruitingPhase 3
Study of a new drug for PNH patients with anemia despite current treatment
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
Beijing, Beijing MunicipalityAges 18–75 - NCT07122167Recruiting
Study of a drug-coated stent for blocked leg arteries
This study is testing a new drug-coated stent for blocked arteries in the thigh or behind the knee. It may help people with moderate to severe leg pain or wounds by improving blood flow without needing surgery.
Chrzanów, ChrzanowAges 18–80 - NCT07123402Enrolling by invitationPhase 2
TRD205 for chronic pain after surgery
This trial tests a new tablet called TRD205 for people who have had long-lasting nerve pain after surgery (at least 3 months). The goal is to see if it can reduce pain safely.
BeijingAges 18–80 - NCT07117240Enrolling by invitationPhase 4
GLP-1 drugs for steroid-induced diabetes
This trial tests whether a GLP-1 receptor agonist (a type of diabetes medication) can safely and effectively treat high blood sugar caused by long-term steroid use. It may help people with type 2 diabetes or steroid-induced diabetes who take oral steroids for conditions like asthma, arthritis, or kidney disease.
Warsaw, WarsawAges 18 years+ - NCT07122024RecruitingPhase 4
Testing a dual therapy for H. pylori treatment
This trial tests a two-drug treatment (keverprazan and amoxicillin) for people who have H. pylori and have not been treated for it before. The goal is to see if this newer combination works well and is safe.
Hangzhou, ZhejiangAges 18–65 - NCT07120282RecruitingPhase 2
Tislelizumab after surgery for early-stage lung cancer
This trial tests whether a drug called tislelizumab, given after surgery, can help prevent lung cancer from coming back. It is for people with stage I non-small cell lung cancer who have certain high-risk features and a protein called PD-L1 on their tumor cells.
BeijingAges 18 years+ - NCT07117864Recruiting
T-DXd with brain radiation for HER2+ breast cancer
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07119021RecruitingPhase 4
Ultra-early stroke treatment with neuroprotection and clot removal
This trial tests a new approach for treating acute ischemic stroke within 4.5 hours of symptoms starting. It combines a special mobile stroke unit that delivers early brain-protecting medicine with standard clot-busting or clot-removal procedures, to see if this can improve recovery.
BeijingAges 18–80 - NCT07115992Recruiting
Surgery with or without radiation for prostate cancer
This trial compares radical prostatectomy (surgery to remove the prostate) alone versus surgery plus pelvic lymph node removal, with or without additional radiation, for men with intermediate- or high-risk prostate cancer that has not spread. It aims to see which approach is more effective and safe.
ShanghaiAges 18–80 - NCT04435990RecruitingPhase 3
Allergy shots for dust mites in teens and adults
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
Santiago de Compostela, A CoruñaAges 12–65 - NCT04898283RecruitingPhase 3
Allergy shot study for grass and cypress pollen symptoms
This phase 3 trial tests a specific allergy treatment (an “immunotherapy” shot) for people whose symptoms are triggered by grass and cypress tree pollen. It aims to see if the treatment is safer and more effective at reducing allergy symptoms over time, especially for nose/eye symptoms and some people with asthma.
Valladolid, Castille and LeónAges 12–65 - NCT07106814RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy (Meta10-TIL) made from your own immune cells that were trained to attack cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including cervical, liver, lung, breast, ovarian, head and neck, or colorectal cancer.
Hefei, AnhuiAges 19–70 - NCT07113262RecruitingPhase 3
Study of IBI311 for people with inactive thyroid eye disease
This trial tests a new medication called IBI311 for people whose thyroid eye disease is no longer active but still causes bulging eyes. It aims to see if the drug can reduce eye bulging safely.
Shenyang, LiaoningAges 18–80 - NCT07115485RecruitingPhase 2
Study of HLX43 for advanced stomach or junction cancer
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
BeijingAges 3 weeks–2 months - NCT07115277Recruiting
A new imaging test for prostate cancer that has come back
This study tests a new imaging drug called Flotufolastat F-18 to find prostate cancer that has returned after treatment. The goal is to see how well and safely it finds the cancer spots, which could help guide next steps.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07110415RecruitingPhase 4
Yangxinshi tablets for heart disease with reduced heart function
This trial tests whether Yangxinshi tablets can help people with coronary heart disease and some degree of heart failure. It looks at improving heart function and safety over the treatment period.
Haozhou, AnhuiAges 40–80 - NCT07106892RecruitingPhase 2
Testing HLX43 for advanced colorectal cancer
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
BeijingAges 3 weeks–2 months - NCT07106580RecruitingPhase 1/Phase 2
Fecal transplant capsules for clearing drug-resistant bacteria from the gut
This trial tests whether taking capsules containing processed healthy donor stool (fecal microbiota transplant) can safely remove certain drug-resistant bacteria (like CRE, ESBL-E, and VRE) from your intestines. It may be an option for people who have these bacteria in their stool but are not currently being treated with antibiotics.
RijekaAges 18 years+ - NCT07114419RecruitingPhase 2
New weekly injection for weight loss in overweight or obesity
This study tests a new weekly injection, efsubaglutide alfa (a GLP-1 drug), for helping people with overweight or obesity lose weight. It is for people who have not been able to lose weight with diet and exercise alone and do not have other serious health conditions.
BrookvaleAges 18–75 - NCT07106723RecruitingPhase 2
Study of stem cell transplant and CD7-CART for T-cell lymphoma
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07107659RecruitingEarly Phase 1
Testing ONT01 for active lupus
This trial tests a new drug called ONT01 for people with active lupus that is not affecting their kidneys. It is for those who have not had success with standard treatments.
New York, New YorkAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.